


Frontiers in Clinical Drug Research (Diabetes and Obesity)



**Editor:
Shazia Anjum**

Bentham Books

Frontiers in Clinical Drug Research- Diabetes & Obesity

(Volume 7)

Edited by

Shazia Anjum

*Institute of Chemistry
The Islamia University of Bahawalpur
Bahawalpur
Pakistan*

Hi qvlt ulp'EnplecnF t wi 'T guct ej '6'F kcdgvu'c pf 'Qdguw{

Volume # 7

Editor: Shazia Anjum

ISSN (Online): 2352-3220

ISSN (Print): 2467-9607

ISBN (Online): 978-981-5123-58-6

ISBN (Print): 978-981-5123-59-3

ISBN (Paperback): 978-981-5123-60-9

©2023, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2023.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	ii
CHAPTER 1 CLINICAL AND DIAGNOSTIC IMPLICATIONS OF GLYCATED ALBUMIN IN DIABETES MELLITUS: AN UPDATE	1
<i>Km Neelofar, Jamshed Haneef and Farah Khan</i>	
INTRODUCTION	1
Non-enzymatic Glycation	2
Non-enzymatic Glycation in Diabetes	3
Human Serum Albumin	4
Albumin Structure Upon Glycation	6
Biological Properties of Albumin Upon Glycation	7
Immunological Properties of Albumin Upon Glycation	8
Glycated Albumin as a Diagnosis Marker	9
Glycated Albumin Measurements	11
CONCLUDING REMARKS	13
CONSENT FOR PUBLICATION	13
CONFLICT OF INTEREST	13
ACKNOWLEDGEMENTS	13
REFERENCES	13
CHAPTER 2 CURRENT STRATEGIES OF NEW DRUGS FOR DIABETES MANAGEMENT	22
<i>Maliha Sarfraz, Rahman M. Hafizur, Hayat Ullah, Sanaulah Sajid, Rana Waseem Akhtar, Mamoona Noreen, Shazia Perveen and Misbah Ullah Khan</i>	
INTRODUCTION	23
CURRENT TREATMENTS FOR TYPE-2 DIABETES MELLITUS	25
Thiazolidinediones	25
Biguanide	26
Sulfonylureas	26
Meglitinides	27
SGLT2 Inhibitors	28
Insulin	28
Incretin Mimetics	30
COMPLEMENTARY TREATMENTS FOR THE MANAGEMENT OF T2D	30
NATURAL PRODUCTS WITH ANTI-DIABETIC PROPERTIES	31
CURRENT AND FUTURE THERAPIES FOR TYPE 1 DIABETES	33
STEM CELL THERAPEUTIC APPROACH	34
NANOTECHNOLOGY AND DIABETES	36
EMERGING TECHNOLOGIES FOR DIABETES TREATMENT	37
CONCLUSION	38
FUTURE PERSPECTIVES	39
CONSENT FOR PUBLICATION	40
CONFLICT OF INTEREST	40
ACKNOWLEDGEMENTS	40
REFERENCES	40
CHAPTER 3 DIABETES TYPE II: SHOULD ASPARTAME BE A CONCERN?	48
<i>Arbind Kumar Choudhary</i>	
BACKGROUND	48
Aspartame and Weight Management	50

Aspartame and Glucose Intolerance	50
Aspartame and Insulin Resistance	52
CONCLUSION	53
CONSENT FOR PUBLICATION	53
CONFLICT OF INTEREST	53
ACKNOWLEDGEMENTS	53
REFERENCES	54
CHAPTER 4 MENTAL HEALTH, ADHERENCE, AND SELF-MANAGEMENT AMONG CHILDREN WITH DIABETES	59
<i>Beáta Erika Nagy, Brigitta Munkácsi and Karolina Eszter Kovács</i>	
INTRODUCTION	60
MENTAL HEALTH AND T1DM	60
Quality Of Health And Diabetes	60
Self-Rated Health In Diabetes	64
Illness Representations	65
FACTORS INFLUENCING ADHERENCE	66
Adherence In Adolescence	67
Factors Influencing Diabetes-Specific Adherence	69
<i>The Characteristics Of The Illness And The Related Factors</i>	70
<i>Intrapersonal Factors</i>	71
<i>Interpersonal Factors</i>	72
<i>Environmental Factors</i>	72
THE PURPOSE OF THE STUDY: THE CONNECTION BETWEEN MENTAL HEALTH, ADHERENCE AND DIABETES	73
Sample Characteristics	73
<i>Experimental Group: Children Diagnosed With Type-1 Diabetes</i>	74
<i>Control Group</i>	77
Applied Tools	78
Demographic Questions	78
The Creation of the Diabetes-Specific Adherence Questionnaire	78
<i>The Factor Analysis Of The Questionnaire</i>	79
Children Depression Inventory (CDI) [133]	81
World Health Organization Well-Being Index (WBI-5) [134]	81
Self-rated Health (SRH) [135]	81
Psychological Mood and Somatic Symptoms [136]	81
Satisfaction with Life, SWL-present (SWL-p) SWL-future (SWL-f), Cantril-ladder [137]; Life Evaluation Index [138]	82
Pediatric Quality of Life Inventory, PedsQL Measurement Model [139, 140]	82
Satisfaction with Life Scale (SWLS) [141]	83
Strengths and Difficulties Questionnaire (SDQ) [142]	83
Research Questions and Hypotheses	83
RESULTS	84
The General Description of Adherence	84
The Relationship Between Adherence and the Indexes of Mental Health	89
Psychological Factors Influencing Adherence	93
SUMMARY	100
Sociodemographic Factors Influencing Adherence	101
Psychological Factors Influencing Adherence	102
CONCLUSION	103
CONSENT FOR PUBLICATION	105

CONFLICT OF INTEREST	105
ACKNOWLEDGEMENTS	105
REFERENCES	105
CHAPTER 5 RECENT TRIALS ON THE CARDIOPROTECTIVE EFFECTS OF NEW GENERATION ANTI-DIABETIC AND LIPID-LOWERING AGENTS	117
<i>Omar M. Abdelfattah, Ahmed Sayed, Anas Al-Refaei, Jasmin Abdeldayem, Khaled Moustafa, Nicholas Elias and Yehia Saleh</i>	
INTRODUCTION	118
SODIUM/GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2I)	128
History, Mechanisms, and Pleiotropic Effects of SGLT2i	128
Pivotal Clinical Trials Involving SGLT2i	129
Dual SGLT1/2 Inhibitors: The Next Step in the Evolution of SGLT2i?	131
INCRETINS	133
History of Incretins and their Mechanisms of Action	133
Safety and Efficacy of DDP-4i	134
Trials Evaluating the Safety and Efficacy of GLP-1ras	136
Summary and Synthesis of the Literature on Incretins	139
INSULIN	142
A Historical Overview of the Discovery of Insulin	142
The Role of Glycemic Control In Outcome-optimization and a Discussion of Trials on Recent Insulin Formulations	142
ALPHA-GLUCOSIDASE INHIBITORS	145
THIAZOLIDINEDIONES	145
Comparison of the Different Novel Modalities and Critical Gaps in the Literature	147
LIPID-LOWERING THERAPIES STATINS	148
Historical Context and Foundational Trials (Pre-2010)	148
Contemporary Analyses and Trials (2010 and Onwards)	150
PCSK9 INHIBITORS	151
Rationale and Initial Discoveries	151
Trials Demonstrating LDL-Lowering Efficacy	152
Evidence of Clinical Efficacy and Reduction of Hard Outcomes	153
OMEGA-3 FATTY ACIDS	155
CONCLUSION	157
CONSENT FOR PUBLICATION	158
CONFLICT OF INTEREST	158
ACKNOWLEDGEMENTS	158
REFERENCES	158
CHAPTER 6 DIABESITY AND THE KIDNEY	168
<i>Mohamed E. Elrggal, Ahmed Elkerai, Sol Carriazo, Hany Sawaf, Si Yuan Khor, Yasmine Elkerai, Issa Haddad, Khaled Moustafa and Mohamed Hassanein</i>	
INTRODUCTION	168
Epidemiology and Genetic Aspects Shared in Diabetes and Kidney Diseases	171
Pathophysiologic Mechanisms Cross-linking Diabetes and Kidney Diseases	173
<i>Obesity</i>	173
<i>Diabetes</i>	174
<i>Diabetes</i>	176
<i>Non-Pharmacological Management</i>	178
A. Exercise	178
B. Dietary Therapy	178
C. Behavioral Modifications	179

<i>Pharmacological Treatment for the Management of Diabesity and Related Kidney Disease</i>	179
ANTI-DIABETIC MEDICATIONS	180
GLP-1 Receptor Agonists	180
<i>Liraglutide</i>	181
<i>Dulaglutide</i>	182
<i>Semaglutide</i>	182
<i>SGLT2 Inhibitors</i>	184
<i>Metformin</i>	184
ANTI-OBESITY MEDICATIONS	185
Orlistat	185
Phentermine/topiramate	185
Naltrexone/bupropion	186
<i>Surgical Options to Control Diabesity and Kidney Disease</i>	187
<i>Future Pipeline Treatment</i>	190
<i>Tirzepatide</i>	190
<i>Cotadutide</i>	192
<i>Amylin Analogs</i>	192
<i>Leucine/Metformin/Sildenafil Combination</i>	193
CONCLUSION	193
CONSENT FOR PUBLICATION	193
CONFLICT OF INTEREST	194
ACKNOWLEDGEMENTS	194
REFERENCES	194
SUBJECT INDEX	20:

PREFACE

Causes of diabetes are so complex but type II diabetes is directly linked with obesity at any time of your age particularly if you have excessive fats around your tummy. Obesity triggers your body's metabolism which causes fat tissues to release fats into your blood that directly affect insulin response and make you insulin sensitive- that's why obesity causes prediabetes. In order to understand this complex pathological disorder in our body and thereafter solutions to surpass this challenge, volume 7 of our eBook series is dedicated to cutting-edge articles on Diabetes or Obesity. The update can be found in the first chapter of this present volume that non-enzymatic glycation of proteins, lipids, and fatty acids speeds up due to persistent hyperglycemia and eventually causes associated secondary complications in diabetes.

The authors in the second chapter describe the current strategies of new drugs for diabetes management. For example, the development of novel therapeutic groups such as amylin analogs, incretin mimetics, GIP analogs, active peroxisome proliferator receptors, and dipeptidyl peptidase-4 inhibitors and as well as bioactive compounds from herbs.

The third chapter of this series deals with the debatable topic of using aspartame for T2D patients. More research is still needed to establish the pathological role of aspartame use in T2D.

Chapter four of this volume covers the research to investigate the psychological characteristics and adherence of children and adolescents with Type 2 diabetes. A joint venture of the Faculty of Medicine and Faculty of Arts has developed that mapping mental health and various therapeutic procedures, as well as their positive and negative effects, are of paramount importance for both diabetes and obesity.

The fifth chapter of this volume is about the clinical trials of new-generation anti-diabetic and lipid-lowering agents that also have simultaneously cardioprotective effects.

The sixth chapter of this volume describes that the kidneys are a vulnerable target of diabetes. In this chapter, the epidemiology, pathophysiology, and treatment of diabetes-induced kidney disease are discussed. The special focus on the therapeutic targets and pharmacological management of diabetes-related kidney diseases is described herein.

I hope that the current volume of this series will provide updated information about the recent developments in Diabetes & Obesity treatment for interested researchers and pharmaceutical scientists. I would like to thank the editorial staff, particularly Mr. Mahmood Alam (Director Publications) and Ms. Asma Ahmed (Senior Manager Publications) for their dedicated efforts and the hard work.

Shazia Anjum
Institute of Chemistry
The Islamia University of Bahawalpur
Bahawalpur
Pakistan

List of Contributors

Ahmed Sayed	Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Anas Al-Refaei	Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Ahmed Elkerai	Kidney and Urology Center, Alexandria, Egypt Faculty of Medicine, Alexandria University, Alexandria, Egypt
Arbind Kumar Choudhary	Department of Physiology, All India Institute of Medical Science (AIIMS) Raebareli, Uttar Pradesh (U.P.), India
Beáta Erika Nagy	University of Debrecen, Faculty of Medicine, Institute of Pediatrics, Pediatric Psychology and Psychosomatic Unit, Hungary
Brigitta Munkácsi	University of Debrecen, Faculty of Medicine, Institute of Pediatrics, Pediatric Psychology and Psychosomatic Unit, Hungary
Farah Khan	Department of Biochemistry, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi 110062, India
Hayat Ullah	Department of Chemistry, University of Okara, Okara 56300, Punjab, Pakistan
Hany Sawaf	Cleveland Clinic Foundation, Cleveland, OH, United States
Issa Haddad	Michigan State University, East Lansing, MI, United States
Jamshed Haneef	Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, Hamdard Nagar, New Delhi 110062, India
Jasmin Abdeldayem	Department of OB/GYN, Texas Tech University Health Sciences Center, El Paso, TX, USA
Km Neelofar	Department of Biochemistry, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi 110062, India
Karolina Eszter Kovács	Faculty of Arts, Institute of Psychology, Department of Pedagogical Psychology, Hungary
Khaled Moustafa	Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt Faculty of Medicine, Alexandria University, Alexandria, Egypt
Maliha Sarfraz	Department of Zoology, Wildlife and Fisheries University of Agriculture Faisalabad Sub Campus, Toba Tek Singh 36050, Pakistan
Mamoona Noreen	Department of Zoology, Wildlife and Fisheries University of Agriculture Faisalabad Sub Campus, Toba Tek Singh 36050, Pakistan
Misbah Ullah Khan	Center for Nano-Sciences, University of Okara, Okara 56300, Punjab, Pakistan
Mohamed E. Elrggal	Kidney and Urology Center, Alexandria, Egypt
Mohamed Hassanein	University of Mississippi Medical Center, Jackson, MS, United States
Nicholas Elias	Department of Internal Medicine, Morristown Medical Center, Atlantic Health System, Morristown, New Jersey, USA

- Omar M. Abdelfattah** Department of Internal Medicine, Morristown Medical Center, Atlantic Health System, Morristown, New Jersey, USA
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
- Rahman M. Hafizur** Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences (ICCBS), University of Karachi, Karachi 75270, Pakistan
- Rana Waseem Akhtar** Faculty of Veterinary and Animal Sciences, Muhammad Nawaz Shareef University of Agriculture, Multan, Pakistan
- Sanaullah Sajid** Institute of Microbiology, University of Agriculture Faisalabad, Pakistan
- Shazia Perveen** Department of Zoology, Wildlife and Fisheries University of Agriculture Faisalabad Sub Campus, Toba Tek Singh 36050, Pakistan
- Sol Carriazo** Department of Nephrology and Hypertension, IIS-Foundation Jimenez-Dia-UAM, Madrid, Spain
- Si Yuan Khor** Michigan State University, East Lansing, MI, United States
- Yasmine Elkerai** Kidney and Urology Center, Alexandria, Egypt
- Yehia Saleh** Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA

CHAPTER 1

Clinical and Diagnostic Implications of Glycated Albumin in Diabetes Mellitus: An Update

Km Neelofar^{2,*}, Jamshed Haneef¹ and Farah Khan²

¹ Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, Hamdard Nagar, New Delhi 110062, India

² Department of Biochemistry, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi 110062, India

Abstract: In diabetes mellitus (DM), non-enzymatic glycation of proteins, lipids, and fatty acids is accelerated due to persistent hyperglycemia and plays an important role in diabetes and its associated secondary complications. Glycation has the potential to alter the biological, structural, and functional properties of macromolecules. Glycated products (early and late) are both involved in provoking the immune-regulatory cells and generating autoantibodies in diabetic patients. More precisely, human serum albumin is the most abundant protein in circulation involved in glycation. Glycated albumin may accumulate in the body tissues of diabetic patients and participate in its secondary complications. This chapter compiles the studies focused on changes in the secondary and tertiary structure of proteins upon glycosylation. Various *in-vitro* and *in-vivo* approaches involved in investigating such changes are systematically reviewed. Besides, the potential role of glycated albumin in the pathogenesis of diabetes mellitus, as well as its applicability as a diagnostic marker in the progression of the disease, is also highlighted.

Keywords: Hyperglycemia, Non-enzymatic glycation, Glycated Albumin, Protein glycation, Diabetes.

INTRODUCTION

Diabetes mellitus (DM) is a metabolic disorder resulting from defects in insulin secretion and/ or action Author, or both. It is characterized by hyperglycemia, polydipsia, glucosuria, and polyuria. In type 1 diabetes, there is a complete absence of insulin, which affects the metabolism of proteins, carbohydrates, and fats. It is a very common autoimmune disease nowadays, afflicting millions of people in India and worldwide also. The disease occurs as a consequence of the organ-specific immune destruction of insulin-producing beta cells within the

* Corresponding author Km Neelofar: Department of Biochemistry, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi 110062, India; E-mail: neloferbiotech@gmail.com

pancreas. However, type 2 diabetes mellitus is the result of the inability of islet beta cells to produce adequate insulin and has become an epidemic. The global prevalence of diabetes in 2011 was 366 million; however, by 2030, it is expected to reach 552 million [1]. Type 2 diabetes mellitus is highly prevalent and accounts for 90–95% of cases. In 21st century, diabetes will be a huge burden due to its increasing global prevalence and higher frequency of chronic complications (nephropathy, retinopathy, neuropathy, and cardiovascular disease), affecting various tissues, difficulty in controlling the disease, and its high cost. During diabetes, persistent hyperglycaemia leads to non-enzymatic glycation of various proteins such as haemoglobin, proteins of the erythrocyte membrane, insulin, human serum albumin (HSA), high and low-density lipoproteins, IgM, IgG, collagen, and histones [2, 3]. Proteins are glycated when glucose is chemically bound to amino groups of proteins without the help of an enzyme, which many structural and conformational changes in protein and proceeds to various micro and macro complications in diabetic patients [4].

Non-enzymatic Glycation

Prof. Louis Camille Maillard gave Maillard reaction after his own studies describing the brown colour formed while heating carbohydrate and amine mixtures. It was first described during the early 20th century. Non-enzymatic glycation is a common chemical modification that involves the condensation of a carbohydrate's aldehyde group with either the epsilon group of lysine, hydroxylysine, side chains of arginine, cysteine, and histidine residues [5] or the alpha-amino group of a protein's N terminal amino acid [6]. Only open forms of sugars react with proteins, and a labile aldimine (Schiff base) is formed in a few hours by attaching protein amino group with sugar *via* nucleophilic attack. This product is reversible and can go back to glucose and protein again, or it can form ketoamine, which is slightly reversible. Further, this can undergo intermolecular rearrangement through acid-base catalysis to form 1-amino-1-deoxy fructose (fructosamine), a more stable early glycated product named amadori product in a few days. Both Schiff base and amadori products *in vivo* predominantly exist in the cyclic form [7]. Further, the stable amadori product gradually evolves to a heterogeneous population of fluorescent adducts with new cross-links, which are called advanced glycation end products (AGEs) by irreversible chemical reactions involving oxidation and fragmentation [8] (Fig. 1). Thus, by subsequent degradation of amadori products and the fragmentation of Schiff base, alpha dicarbonyl compounds and alpha-keto aldehydes formed, respectively (Fig. 2) [9]. Throughout the 1980s and 1990s, a large body of evidence has implicated that AGEs are mediators of various complications of diabetes and aging. The AGEs also interact with various AGE receptors as RAGEs and stimulate signaling pathways that are important to cause long-term complications in diabetic patients.




Fig. (1). Non-enzymatic glycation of protein by glucose and production of early and late glycation product. [Source; (Km Neelofar *et al.*, 2015).




Fig. (2). Amadori adduct fate (Km Neelofar *et al.*, 2015).

Non-enzymatic Glycation in Diabetes

Recent studies demonstrate that non-enzymatic glycation is accelerated during hyperglycemia, and its products are aggressively involved in the pathogenesis of diabetes. In diabetes, persistent hyperglycemia leads to non-enzymatic glycation of various proteins such as hemoglobin, proteins of the erythrocyte membrane, insulin, IgG, IgM, human serum albumin, high and low-density lipoproteins, collagen, and histones. Non-enzymatic glycation is also found in normal conditions, but in diabetes, it is increased [10]. Glycated serum proteins consider a marker for hyperglycaemia in diabetes mellitus. Our research studies have shown that early glycation products induced significant changes in albumin structure and function [11]. Glycated proteins are involved in disease pathogenesis by

CHAPTER 2

Current Strategies of New Drugs for Diabetes Management

Maliha Sarfraz^{1,*}, Rahman M. Hafizur², Hayat Ullah^{3,*}, Sanaullah Sajid⁴, Rana Waseem Akhtar⁵, Mamoon Noreen¹, Shazia Perveen¹ and Misbah Ullah Khan⁶

¹ Department of Zoology, Wildlife and Fisheries University of Agriculture Faisalabad Sub Campus, Toba Tek Singh 36050, Pakistan

² Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences (ICCBS), University of Karachi, Karachi 75270, Pakistan

³ Department of Chemistry, University of Okara, Okara 56300, Punjab, Pakistan

⁴ Institute of Microbiology, University of Agriculture Faisalabad, Pakistan

⁵ Faculty of Veterinary and Animal Sciences, Muhammad Nawaz Shareef University of Agriculture, Multan, Pakistan

⁶ Center for Nano-Sciences, University of Okara, Okara 56300, Punjab, Pakistan

Abstract: Several aspects need to be explored in drug therapy for diabetes patients. Some specific glucose-reducing medicines are present, while other medicines are associated with unintentional changes in hyperglycemia. Diabetes is a developing epidemic that has caused significant socioeconomic problems in several countries throughout the world. Despite scientific discoveries, greater healthcare services, and higher literacy rates, the disease continues to plague many industries, particularly developing countries. The current trends show an increase in premature mortality, which threatens world prosperity. Experimental and technical improvements have been made in sulphonylureas, alpha-glucosidase inhibitors, biguanides, and thiazolidinediones, all of which are beneficial in lowering glucose levels. The latest drug research techniques have led to the development of novel therapeutic groups such as amylin analogs, incretin mimetics, GIP analogs, active peroxisome proliferator receptors, and dipeptidyl peptidase-4 inhibitors as targets for future diabetes therapy medications. Furthermore, drug development and detection for diabetes treatment have been revolutionized by identifying and investigating bioactive compounds from herbs. This chapter discusses vital fields of clinical diabetology regarding opportunities for stem cells and nanotechnology as next-generation therapies, with an emphasis on evolving developments and reviews why plant-derived products are reliably common for treating and managing diabetes.

* **Corresponding authors Maliha Sarfraz and Hayat Ullah:** Department of zoology wildlife and fisheries university of agriculture Faisalabad sub campus Toba tek Singh 36050, Pakistan; E-mails: maliha.sarfraz@yahoo.com, hayatullah@uo.edu.pk

Shazia Anjum (Ed.)

All rights reserved-© 2023 Bentham Science Publishers

Keywords: Diabetes, Emerging Trends, Herbal Formulations, Glucose-lowering Drugs.

INTRODUCTION

Diabetes mellitus (DM) is a complicated metabolic condition identical to elevated blood glucose levels or hyperglycemia, resulting from insulin secretion deficiencies, intervention, or both, as displayed in Fig. (1). The persistent metabolic disproportion related to this condition places the patient at increased danger of long-standing macro and microvascular problems, leading to repeated hospitalization and complications, including an elevated danger of cardiovascular disease, unless high-quality treatment is provided [1].




Fig. (1). Diabetes mellitus and its types.

Diabetes is a common and significant global public health concern. According to the International Association of Diabetes (IDF), around 463 million adult diabetes patients were documented worldwide in 2019, which is around 9.3 percent of adults aged 20-79 years, and the number of diabetes patients is still rising [2]. The selection and implementation of glucose control therapy rely on a variety of factors, such as the condition of hyperglycemia, the underlying liver and kidney functions, hypoglycemic risk, the body mass index, capacity to regulate blood

glucose, and drug cost. Type 2 diabetes therapeutics include stimulus for insulin release by GLP analogs such as liraglutide and exenatide [3, 4], insulin injection to balance β -cell defects, inhibition of dipeptidyl peptidase-4 (DPP-4) by sitagliptin, and improved islets survival [5, 6] and islet cell regeneration through islet neogenesis associated protein (INGAP) peptide therapy aiming at islet cell regeneration [7].

Diabetes has become a threat to people's health and is a significant global problem for health and society. A timely clinical concern is diabetes care. Along with diet variety and appropriate workouts, antidiabetic medications are important approaches in the treatment of diabetes. Several hypoglycemic agents, like insulin and insulin analogs, biguanides, sulfonylureas, thiazolidinediones, glinides, alpha-glucosidase inhibitors, dipeptidyl peptidase 4 (DPP4), glucagon-like peptide 1 (GLP-1) receptor agonists, and sodium-glucose cotransporter 2 (SGLT2) inhibitors, are currently used in the treatment of diabetes [8]. However, almost half of patients with diabetes cannot achieve treatment goals, including glycemic control, even over 10 years [9 - 11]. A big confusion about the suitable choice and screening of antidiabetic drugs because of the various hypoglycemic drugs is the accessibility and the possibility that the same hypoglycemic agent may contribute to different beneficial responses in each individual. The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) also propose individualized diabetes attention and precision medicine applications [12, 13]. Providing medication that relates to the genetic knowledge of individuals through pharmacogenomics is one way to achieve precision medicine and direct the proper use of antidiabetic agents [14, 15].

Strategies for the treatment of pharmacologic agents (leptin, β -3-agonists) can increase the resistance of glucose uptake by effectively reducing visceral fat. A function for macrophage fatty-inhibitors (thiazolidinediones, CCR2 antagonists) in treating insulin resistance and vascular disease is also strengthened in different reported studies. Thus, two research lines worth exploring include (i) the interpretation of the visceral fat secretory biology to determine key mediators of the Mets and (ii) drug production for modulative delivery of body fat [16]. Some new kinds of hypoglycemic medicines, such as GLP-1, DPP-IV inhibitors, amylin inhibitors, peroxisome proliferators, and activated receptors, have also been developed and recorded. Any active molecules and bioactive compounds purified from herbs and seeds add to the war on diabetes. These plant components have overturned the production of medicines and led to the discovery of diabetes drugs. Several recent studies have been conducted on important fields of diabetes, focusing more on the statin-based method of diabetes treatment and next-generation antidiabetic stem cell therapy [17].

Diabetes Type II: Should Aspartame be a Concern?

Arbind Kumar Choudhary¹

¹ Department of Physiology, All India Institute of Medical Science (AIIMS) Raebareli, Uttar Pradesh (U.P.), India

Abstract: Blood sugar levels have to be controlled by individuals with type II diabetes (T2D) to preserve health and longevity. For such people, artificial sweeteners (including aspartame) are proposed sugar substitutes. In particular, the protection of aspartame has long been the point of discussion. Although it is such a problematic product, T2D patients are advised by many physicians to use it during a managed diet and as part of a treatment modality. Aspartame is 200 times sweeter than sugar and has a marginal effect on blood glucose levels. It is recommended for use so that T2D can regulate carbohydrate consumption and blood sugar levels. Previous studies, however, indicate that aspartame consumption may increase a person's risk of gaining weight instead of losing weight, resulting in intolerance to blood glucose in T2D. By increasing the levels of cortisol, aspartame can act as a biochemical stressor. It may cause systemic oxidative stress by creating excess free radicals, altering the gut's microbial activity, and interacting with the receptor N-methyl D-aspartate (NMDA), resulting in insulin deficiency or tolerance. Due to the lack of reliable evidence, aspartame and its derivatives are safe for T2D yet are still debatable. In the already stressful physiology of T2D, more research is needed to provide indications and raise concerns that aspartame may worsen the prevalence of pathological physiology.

Keyword: Aspartame, Aspartic acid, Methyl alcohol, Phenylalanine.

BACKGROUND

Non-nutritive sweeteners are commonly used by people who want to minimize their average daily calorie consumption, lose weight, and maintain a balanced diet [1]. Non-nutritive sweeteners elicited physiological responses, although inconsistent, but failed to reduce blood glucose levels [2]. Aspartame is a non-nutritive sweetener that has gotten a lot of attention because of its extreme sweetness, 200–300 times sweeter from sucrose [3]. The European Food Safety

* **Corresponding author Arbind Kumar Choudhary:** Department of Physiology, All India Institute of Medical Science (AIIMS) Raebareli, Uttar Pradesh (U.P.), India; E-mail: arbindchoudhary111@gmail.com

Authority (EFSA) recommends 40 mg/kg.BW/day of aspartame, while the Food and Drug Administration (FDA) recommends 50 mg/kg.BW/day [4, 5]. Health-conscious people and diabetic patients use aspartame products, but their safety is a major concern (Fig. 1).




Fig. (1). Safety dosage of aspartame and safety issues.

Diabetes mellitus, *i.e.*, type II diabetes (T2D), is a metabolic disorder in which the pancreas fails to produce sufficient insulin. The body cells fail to respond to the insulin produced correctly. This results in chronic hyperglycemia (high blood glucose levels) and disturbances in carbohydrate, fat, and protein metabolism. In the long run, this may lead to symptoms of this disorder such as retinopathy, nephropathy; neuropathy; and an elevated risk of cardiovascular disease. A balanced diet, daily physical activity, and pharmacotherapy are all recommended for diabetes management. As for many people, the most critical component of the treatment regimen for diabetes is deciding on what to eat.

Aspartame and Weight Management

Although aspartame is suggested to help people lose weight by reducing their food intake and limiting their calorie intake [6], compared to natural sweeteners like sucrose, aspartame may have no impact on food consumption, satiety levels, or postprandial glucose levels. It may also not affect postprandial insulin levels [7]. Although aspartame can help with weight loss by lowering caloric intake when compared to sucrose [6], there is evidence that rats can compensate for the calorie reduction by overeating, resulting in increased body weight and adiposity [8]. It is well known that type 2 diabetes (T2D) and obesity have a troubling relationship [9].

Humans with a higher BMI were found to consume diet carbonated drinks containing aspartame [10, 11]. The increasing use of aspartame (*e.g.*, Diet Coke) in food items has been related to weight gain [12]. Aspartame is thought to disrupt appetite control and contribute to weight gain. It does not stimulate the food reward pathways in the same way that natural sweeteners do but instead encourages sugar craving and sugar dependency, leading to weight gain [12]. For some people, eating dietary foods justifies consuming excess calories from other kinds of food. As a result, it's impossible to say if obesity is linked to the usage of artificial sweeteners (including aspartame) or just to eat too many calories [13].

Weight changes are typically connected to insulin receptors or insulin resistance changes [14]. Increased insulin and glucose levels are linked to weight gain [15]. Chronically high insulin levels are linked to a loss of insulin sensitivity [16], leading to insulin resistance [14]. Insulin resistance is believed to be related to elevated blood sugar, triglycerides, blood clots, insomnia, and cardiovascular and neurological disease [17 - 19].

Although replacing added sugars in foods and beverages with aspartame has the potential to improve body weight and glucose control. The American Diabetes Association and the American Heart Association said in a scientific statement that evidence for their long-term benefits in reducing caloric and added sugar intake is limited.

Aspartame and Glucose Intolerance

Glucose intolerance is commonly accepted as a precursor to T2D [20]. In human [7, 21, 22] and animal studies [23-25], the role of aspartame in maintaining an average blood glucose level is debatable. Although no major variations in blood glucose levels were found [7, 22], it did not sustain an average level. It increased blood glucose levels [23, 25, 26]. Gut enzymes (esterase and peptidase) easily break down aspartame into its three metabolic components: phenylalanine (50%),

CHAPTER 4

Mental Health, Adherence, and Self-Management Among Children with Diabetes

Beáta Erika Nagy¹, Brigitta Munkácsi¹ and Karolina Eszter Kovács^{2,*}

¹ University of Debrecen, Faculty of Medicine, Institute of Pediatrics, Pediatric Psychology and Psychosomatic Unit, Hungary

² Faculty of Arts, Institute of Psychology, Department of Pedagogical Psychology, Hungary

Abstract: Nowadays, the investigation of mental health is a popular and important topic. Several national and international researchers have been trying to discover the different mechanisms, effects and efficacy among healthy people and patients diagnosed with chronic diseases. It is particularly important to monitor this phenomenon in childhood and adolescence regularly. The developmental processes are further hampered by the physical, mental, social and spiritual development due to the different illnesses. Therefore, it is clear that mapping mental health and various therapeutic procedures, as well as their positive and negative effects, are of paramount importance in diabetes and obesity.

In this research, after analysing the scales of ten international questionnaires, a complex Diabetes Adherence Questionnaire with 58 statements was created, the characteristics and subscales of which (1. Self-management; 2. Emotional feedback - emotional reactions associated with blood sugar level measurement; 3. Social support - parents and family; 4. Social support - peer relationships; 5. Denial of the disease; 6. Positive consequences of adherence; 7. Negative consequences of adherence, pain, discomfort, burden; 8. Relationship with the medical team; 9. Concern about the future) are described in the present book chapter. We also introduce our latest research findings on the relationship between adherence and mental health, covering self-evaluated health and quality of life, satisfaction with life, subjective well-being, vision and depression, stating that positive variables show a positive while negative variables correlate negatively with adherence.

Keywords: T1DM, Adherence, Denial of the disease, Depression,, Diabetes Adherence Questionnaire, Emotional feedback, Negative adherence (the burden of the treatment), Positive adherence, Quality of life, Self-management, Self-rated

* Corresponding author Karolina Eszter Kovács: Faculty of Arts, Institute of Psychology, Department of Pedagogical Psychology, Hungary; Tel: +36 52 512 900/22533; E-mail: karolina92.kovacs@gmail.com

health, Social support (medical team) vision (worries), Social support (parents and family), Social support (peer relationships).

INTRODUCTION

According to the latest statistics of the International Diabetes Atlas, Type 1 Diabetes (T1DM) is one of the fastest-growing global health problems of the 21st century [1, 2]. Epidemiological surveys show that its incidence and prevalence are continuously increasing worldwide, affecting all age groups, regardless of gender and socio-economic background. As diabetes has a significant impact on children's physical health and their mental, emotional, and social development [3, 4], continuous and in-depth exploration of T1DM and related factors is of paramount importance. Chronic diseases such as diabetes require adequate adherence to the treatment protocol, in this case, regular insulin dosage, blood glucose measurement, and proper diet [5]. However, its quality can be supported or hindered by several intra- and interpersonal as well as environmental factors [6]. Adherence, which is 'the individual's behaviour in accordance with recommendations agreed with a health care professional in medication, diet, and lifestyle change', is thus a complex phenomenon that also requires a complex definition to study. However, the questionnaires and other research methods applied in international practice to study adherence do not cover adherence in complexity but focus only on one spectrum. Thus, we aimed to create a complex Diabetes Adherence Questionnaire with 58 statements [7]. In this chapter, after introducing the most relevant literature and previous research findings, we present the above-mentioned questionnaire and the most important findings of these topics.

MENTAL HEALTH AND T1DM

Quality Of Health And Diabetes

The concept of quality of life (QoL) has come to the fore in psychology and medicine in recent decades. The term quality of life, interpreted from a psychological point of view, is based on positive psychology and is associated with the subjective well-being and the affective dimension of quality of life [8, 9]. In addition to the general satisfaction, the cognitive components of the quality of life also mean an area-specific assessment related to individual satisfaction, performance, and health [10]. Quality of life is determined by the subjective assessment of the individuals' life and how good or bad they feel about it. Thus, the multidimensional construct that integrates physical, psychological, and social well-being includes both cognitive and emotional elements [11, 12]. First, the study and improvement of quality of life among children with certain somatic diseases, *e.g.* diabetes, cardiac disease and epilepsy, have appeared. Concerning

the quality of life, the subjective assessment of an individual's general health, impairments, and routine functioning are significant [13]. When examining the phenomenon, the aspect described for adults is of outstanding importance, according to which an objective external observer is essential in addition to the child's own judgment, so we cannot rely only on the children's subjective evaluation. The use of proxy reports, *i.e.* data based on the opinion of the external reviewer (mostly the parent), is recommended to get a more precise and reliable picture of the situation of children and adolescents. However, parents are 'not entirely' external and objective evaluators, as they have a unique and close relationship with their children. In the case of psychiatric illnesses, both children and parents have reported poorer quality of life than their healthy peers [14, 15]. It is interesting to note that the children's perceptions of themselves and the parents of their children often differ [16, 17]. According to Cummings [18], a comparison of objective and subjective data is essential, and although a weak relationship between objective and subjective indicators can be demonstrated, none can be neglected when examining children [19, 20].

Several studies have examined the extent to which children agree with their parents' perceptions concerning their quality of life [21, 22]. A stronger correlation has been demonstrated concerning the objective areas (*e.g.*, school performance), while a weaker relationship could be detected concerning the child's assessment of the psychological and social situation. Assessing the quality of life of a child can also be influenced by examining the similarities between the evaluation of the parent and the child among both healthy or chronically ill children [23]. Jozefiak *et al.* [22] reported that in the case of healthy children, parents perceive a much more positive status concerning the child's quality of life in almost all areas (except family and friendships) than the children themselves. Hwang *et al.* [24] found that chronically ill adolescents rated their quality of life less poorly than their parents. The reason for this can be that they do not have as much insight into their problems as their parents, so they do not always experience their illness as critical.

Therefore, quality of life is a key factor in gaining a better understanding and more effective treatment concerning people with chronic illnesses. Pediatric health practice also increasingly recognises the importance of integrating illness-specific health-related quality of life (HRQoL) testing into an increasingly holistic approach to disease management [25]. For T1DM, in order to achieve optimal glycemic control, children face serious challenges in their daily lives: having at least 1500 insulin injections within a year, blood glucose measurement with 1000 finger sticks, absence from school of at least 7-15 days due to clinical follow-up examinations, regular contact with the care team, constant self-discipline, and self-control over adherence to the diet. These aspects raise the question of how the

CHAPTER 5

Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents

Omar M. Abdelfattah^{1,2}, Ahmed Sayed³, Anas Al-Refaei³, Jasmin Abdeldayem⁴, Khaled Moustafa⁵, Nicholas Elias¹ and Yehia Saleh^{6,*}

¹ Department of Internal Medicine, Morristown Medical Center, Atlantic Health System, Morristown, New Jersey, USA

² Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA

³ Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

⁴ Department of OB/GYN, Texas Tech University Health Sciences Center, El Paso, TX, USA

⁵ Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt

⁶ Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA

Abstract: Diabetes and hyperlipidemia are global epidemics that significantly increase the morbidity and mortality of the affected population. Several medications have been utilized to mitigate the risk of diabetes and hyperlipidemia. Insulin, alpha-glucosidase inhibitors, thiazolidinediones have been used for decades as antidiabetic medications. Statins are a cornerstone in hyperlipidemia management. Omega-3 fatty acid supplementation has been used to treat hypertriglyceridemia with debatable effects on cardiovascular outcomes.

In the past decade, multiple new discoveries have revolutionized the management of these disorders. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of oral anti-diabetic drugs with a unique mechanism of action. SGLT2 was proven to reduce cardiovascular events, including hospitalization for heart failure, with this benefit extending to patients without diabetes. PCSK9 inhibitors are a new class of antihyperlipidemic that significantly lowers plasma LDL-C on top of the conventional treatment.

In this book chapter, we review the history of diabetes and hyperlipidemia medications and discuss the new classes of lipid-lowering and anti-diabetic medications and their associated cardioprotective benefits.

* **Corresponding author Yehia Saleh:** Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA; Tel: +1 (517) 402-6069; E-mail: yehiatri@gmail.com

Keywords: Anti-diabetic, Cardioprotective, Cardiovascular, Diabetes mellitus, DPP4, Heart failure, Incretin, Lipid, Lipid lowering, Medications, Outcomes, SGLT.

INTRODUCTION

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with diabetes mellitus (DM) [1, 2]. Diabetic patients suffer from microvascular and macrovascular complications, with coronary heart disease (CHD) being the most common cardiovascular disease in diabetic patients.

Data from the UK and Canada suggest a 3% to 5% yearly decline in the rates of acute myocardial infarction (MI), stroke, cardiovascular mortality (CVM), and all-cause mortality (ACM) in patients with diabetes since the early 1990s [2]. However, patients with Type-1 Diabetes Mellitus (T1DM) and Type-2 Diabetes Mellitus (T2DM) still experience a significantly higher cardiovascular risk than the general population [2 - 5], highlighting the importance of cardioprotective medications.

Besides glycemic control, taking additional risk factors into account is also an essential component of the patient's management plan. Smoking, higher LDL levels, and a higher body mass index (BMI) are important risk factors that a holistic patient approach should consider, along with controlling plasma glucose and HbA1c levels [2].

The cardiovascular (CV) safety and benefits of novel anti-diabetic medications have been the focus of recent studies due to the heightened mortality risk in this patient population and the scarcity of evidence linking more traditional anti-diabetics to improved hard cardiovascular outcomes, such as cardiovascular mortality and major adverse cardiovascular events (including strokes and MI) [6]. This improvement in outcomes is essential because reductions in surrogate measures, such as HbA1c, are ultimately not as directly relevant to the patient as their risk of death or stroke. In addition, recent advances in lipidology have further added to the clinician's arsenal of lipid-lowering drugs, which also play a vital role in risk reduction in a variety of relatively high-risk patient populations—including those with diabetes. This chapter will discuss the newer formulations of insulin, anti-diabetic, and lipid-lowering medications and summarize each class' landmark trials, a summary of which is illustrated in Tables 1 and 2.

Table 1. Summary of landmark clinical trials focusing on anti-diabetes medications over the past decade.

Anti-Diabetic Drugs							
SGLT2 Inhibitors							
Trial, Authors, Publication Date,	Recruitment Period	Patient Population	Intervention (Drug Name, Dose)	Control	Sample Size (Intervention vs Control)	Main Outcome(s)	
						Clinically-oriented hard outcomes	Surrogate Outcomes
EMPA-REG Trial, Zinman <i>et al.</i>, 2015 (4)	2010 to 2013	T2DM with established cardiovascular disease with an HbA1c of $\geq 7\%$ and less than 10% (If they had received glucose-lowering medications within the last 12 weeks) or 9% (If they had not received such medications within the last 12 weeks)	Empagliflozin, 10 or 25mg	Placebo	4687 vs 2333	<ul style="list-style-type: none"> - 0.86 HR of CVM, MI or stroke - 38% RRD of CVM - 35% RRD of HF Hospitalization - 32% RRD of ACM 	<ul style="list-style-type: none"> - An HbA1c reduction of 0.24% in the 10mg group and 0.36% in the 25mg group at 206 weeks
CANVAS, Neal <i>et al.</i>, 2017(5)	2009 to 2011 and 2014 to 2017	T2DM with an HbA1c of between 7 and 10.5% and a history of symptomatic ASCVD (Aged ≥ 30 years) or ≥ 2 risk factors for cardiovascular disease (Aged ≥ 50 years)	Canagliflozin, 100 or 300mg	Placebo	5795 vs 4347	<ul style="list-style-type: none"> - 0.86 HR of CVM, MI or stroke - HR of 0.73 for albuminuria progression. 	<ul style="list-style-type: none"> - A mean HbA1c reduction of 0.58%.
CREDESCENCE, Perkovic <i>et al.</i>, 2019(6)	2014 to 2017	T2DM with an HbA1c of 6.5 to 12%** and albuminuric CKD (GFR of between 30 and 90ml/min/1.73m ² in addition to an UACR of between 300 and 5000)	Canagliflozin, 100mg	Placebo	2202 vs 2199	<ul style="list-style-type: none"> - 0.7 HR of End-stage KD, Creatinine doubling, or CVM, or renal mortality - 0.8 HR of CVM, MI or stroke - 0.61 HR of HF Hospitalization 	<ul style="list-style-type: none"> - Overall mean HbA1c reduction of 0.31% throughout the trial
DECLARE-TIMI 58, Wiviott <i>et al.</i>, 2019(7)	2013 to 2018	T2DM with an HbA1c of between 6.5 and 12%, a creatinine clearance of ≥ 60 ml/min, and a history of ASCVD or multiple risk factors thereof.	Dapagliflozin, 10mg	Placebo	8582 vs 8578	<ul style="list-style-type: none"> - 0.83 HR of CVM or HF hospitalization - No statistically significant differences in MACE - No statistically significant differences in CVM 	<ul style="list-style-type: none"> - Average Mean HbA1c reduction of 0.42%
DAPA-HF, McMurray <i>et al.</i>, 2019(8)	2017 to 2018	Heart Failure with NYHA class II-IV and LVEF $\leq 40\%$	Dapagliflozin, 10mg	Placebo	2373 vs 2371	<ul style="list-style-type: none"> - 0.74 HR of HF worsening (Hospitalization or IV therapy) or CVM - 0.82 HR of CVM - 0.83 HR of ACM - Similar effects in both diabetics and non-diabetics 	<ul style="list-style-type: none"> - N/A
VERTIS, Cosentino <i>et al.</i>, 2020 (9)	2013 to 2019	T2DM with an HbA1c of between 7 and 10.5%, established ASCVD, and with a significant proportion of HF/EF $\leq 45\%$ (23.7 and 60.7% respectively)	Ertugliflozin, 5 or 15mg	Placebo	5499 vs 2747	<ul style="list-style-type: none"> - RR of 0.7 for HF hospitalization - No statistically significant differences in CVM 	<ul style="list-style-type: none"> - N/A

Diabetes and the Kidney

Mohamed E. Elrggal¹, Ahmed Elkerai^{1,2}, Sol Carriazo³, Hany Sawaf⁴, Si Yuan Khor⁵, Yasmine Elkerai¹, Issa Haddad⁵, Khaled Moustafa² and Mohamed Hassanein^{6,*}

¹ *Kidney and Urology Center, Alexandria, Egypt*

² *Faculty of Medicine, Alexandria University, Alexandria, Egypt*

³ *Department of Nephrology and Hypertension, IIS-Foundation Jimenez-Diaz-UAM, Madrid, Spain*

⁴ *Cleveland Clinic Foundation, Cleveland, OH, United States*

⁵ *Michigan State University, East Lansing, MI, United States*

⁶ *University of Mississippi Medical Center, Jackson, MS, United States*

Abstract: Diabetes Mellitus and obesity, now coined as “Diabetes”, is a worldwide epidemic that imposes a huge burden on healthcare and society. Diabetes has been associated with poor outcomes and increased morbidity and mortality. The kidneys are a vulnerable target of diabetes. In this chapter, we discuss the epidemiology, pathophysiology, and treatment of diabetes-induced kidney disease. We specifically focus on the therapeutic targets and pharmacological management of diabetes-related kidney diseases.

Keywords: Chronic kidney disease, Diabetes, Diabetic kidney disease, Kidney failure, Obesity.

INTRODUCTION

Diabetes Mellitus (DM) and obesity, now coined as “Diabetes”, is a worldwide epidemic that imposes a huge burden on healthcare and society [1]. Five million deaths in 2015 were attributed to DM in people aged 20–79 years, representing 12.8% of the global all-cause mortality. In 2010, the prevalence of diabetes worldwide was 284 million people, which represented nearly 6.4% of the whole world population and is estimated to reach 642 million by 2040 [2, 3].

* **Corresponding author Mohamed Hassanein:** University of Mississippi Medical Center 2500 North State Street, Jackson 39216, MS, USA; Tel: +16019845670; E-mail: mhassanein@umc.edu

Insulin resistance is the cornerstone of the pathophysiology of diabesity. For every kilogram rise in body weight, there is an increased risk of diabetes by 4.5%. Poor dietary habits, lack of exercise, and other risk factors lead to hyperinsulinemia, insulin resistance (IR), and atherogenic dyslipidemia, *i.e.*, hypertriglyceridemia, low high-density lipoprotein (HDL-C), and increased low-density lipoprotein (LDL-C).

Diabesity predisposes to cardiovascular morbidity and other comorbidities, such as hypertension, endothelial dysfunction, metabolic syndrome, and obstructive sleep apnea. Moreover, diabesity is linked with polycystic ovarian syndrome and various malignancies, such as breast, endometrial, and prostate cancer [3, 4].

The kidney is the most important target of microvascular damage in DM. Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD) worldwide. It is now considered as a “medical catastrophe of worldwide dimension” [5]. Diabetes that affects the kidneys used to be known as Diabetic Nephropathy, however, DKD is now the new term used to encompass a whole spectrum of nephro-pathology induced by DM, since it has been introduced by the Kidney Disease Outcomes Quality Initiative (KDOQI) in 2007 [6].

Genetically speaking, DM can be categorized into a monogenic form, including neonatal and maturity-onset diabetes of the young (MODY), and a polygenic form that includes classic Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM). Studies have shown that DKD in T2DM has not been strictly linked to poor glycemic control as it was more likely to develop in patients with a strong family history of cardiovascular disease [7].

Obesity presents a systemic pro-inflammatory state that promotes IR and DM [8]. Obesity-associated nephropathy is characterized by increased kidney weight and hypertrophy of individual nephrons, increased glomerular size, and reduced glomerular density in the cortex, as well as the number of glomerular capillaries [9].

It's always challenging in patients suffering from diabetes and kidney disease to distinguish between those with non-diabetic CKD [10]. Therefore, despite numerous studies relying on nephro-pathology to differentiate DKD from non-DKD, it remains sometimes difficult to determine the exact incidence of DKD.

In addition to the current advances in understanding DKD, there are some concerns that physicians have regarding optimizing the diagnostic process and future propositions in its management. The natural course of DKD could be divided into five stages: increased glomerular filtration rate (GFR) initially with hyperfiltration, the ‘silent’ phase, the ‘incipient’ phase, the ‘overt’ phase, and

eventually the development of ESKD. Nevertheless, not all patients obviously follow the same course of complications [11].

DKD screening should be done yearly in T1DM starting 5 years after diagnosis and at the time of diagnosis for all patients with T2DM then annually thereafter. Diabetic retinopathy is strongly suggestive of DKD in the presence of albuminuria. To confirm the diagnosis of DKD, albuminuria or reduced estimated GFR (eGFR) should be present in two abnormal measurements at least 3 months apart [12].

The atypical presentation that may denote non-diabetic kidney disease includes sudden onset of low eGFR, rapidly decreasing eGFR, an abrupt increase in albuminuria, development of nephrotic-range proteinuria, development of nephritic syndrome, refractory hypertension, signs or symptoms of another systemic disease, and > 30% eGFR decline within 2–3 months of initiation of a renin-angiotensin system inhibitor [12, 13].

According to the American Diabetes Association, glycemic targets should be tailored to age and other comorbidities. Strict glycemic control, such as hemoglobin A1c (HbA1c) <6.5%, is important for young patients with early diabetes, and those who have not yet developed complications. On the other hand, HbA1c targets up to 8% are allowed for patients with longstanding DM, older age, micro- and macrovascular complications, and limited life expectancy. Similarly, the National Kidney Foundation (NKF)–KDOQI and the Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend a target HbA1c of about 7% to prevent or delay the progression of the microvascular complications of diabetes. However, patients at risk for hypoglycemia, should not target less than that.

Conventional therapy of DKD includes good hyperglycemic control, control of hypertension and hyperlipidemia, antiproteinuric drugs, and close monitoring for micro and macrovascular complications with appropriate management to slow their progression.

Anti-diabetic medications also have an impact on weight in addition to glycemic control. Recent clinical trials on patients with DKD revealed that Sodium-Glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) were capable of improving long-term kidney-related outcomes of DKD in the outpatient clinic [5, 14]. Newer agents to treat obesity are emerging, with efficacy and safety being tested in randomized controlled trials.

SUBJECT INDEX**A**

Absorbing monosaccharides 145
Acid(s) 1, 2, 5, 11, 12, 33, 48, 127, 155, 156,
157, 173, 177
 aspartic 48
 docosahexaenoic 127
 docosahaenoic 155
 eicosapentaenoic 155
 eicosapentaenoic 127
 fatty 1, 33, 127, 155, 156, 157, 177
 terminal amino 2
 thiobarbituric 12
 uric 11, 173
Activation, berberine-induced AMPK 33
Activities 5, 26, 27, 32, 52, 173
 antioxidation 5
 coronary 27
 endocrine 173
 hypoglycemic 26
 mitochondrial 52
 potassium channel blocker 32
Acute coronary syndrome 124
Adipocytes stress 176, 177
Adiponectin 52, 173
 deregulating 52
Adipose tissue 26, 173, 174, 176
 deposition 174
Adolescent(s) 64, 68
 diabetes 68
 healthy 64
Adrenomimeticism 32
Advanced glycated protein 4
Agents 24, 148
 antidiabetic 24
 anti-glycemic 148
Albuminuria 119, 121, 124, 129, 135, 170,
173, 175, 176, 188
 progression 119, 129
Alzheimer's disease 11
Amadori albumin 7
AMP-activated protein kinase 193

Angina 148
Angioedema 181, 183
Antibodies, polyspecific 9
Antidepressants 186
Anti-diabetic 27, 31, 33, 119, 179
 agents 33, 179
 drugs 27, 119
 properties 31, 33
Anti-obesity 180, 185, 193
 medications 180, 185
 vaccines 180, 193
Anti-thymocyte globulin (ATG) 34
Arrhythmias 127, 155, 186
Aspartame consumption 48, 53
Assays 6, 12
 colorimetric 6, 12
 enzyme-linked immunosorbent 12
 green 12
Atherosclerosis 149
Atherosclerotic 133, 141, 148
 cardiovascular disease 141
 disease 133, 148
Atorvastatin 149, 150
ATP-sensitive potassium 26
Autoimmunity 9, 34
Auto-phosphorylation 32

B

Bariatric surgery 180, 187, 188, 189, 190
Biodegradability 37
Blood glucose dysregulation 50

C

Cancer 29, 169, 179, 183
 medullary thyroid 183
 progression 29
 prostate 169
Candida albicans 33
Carbohydrates 1, 5, 30, 31, 49, 143

Carbonic anhydrase 186
Cardiac disease 60
Cardiovascular 2, 4, 23, 30, 49, 117, 118, 119,
124, 125, 128, 129, 134, 139, 146, 155,
157, 179
benefits 128, 129, 134, 146
disease 2, 4, 23, 30, 49, 118, 119, 125, 128,
139, 157
events 117, 124, 128, 134, 155, 157
toxicity 179
Children depression inventory (CDI) 81, 88,
90, 93
Cholecystectomy 182
Cholecystitis 182
Cholelithiasis 182
Cholesterol synthesis, compound inhibiting
148
Chronic 49, 120, 123, 124, 126, 130, 132, 168,
171, 173, 174, 175, 176, 177, 178, 188,
189
hyperglycemia 49, 174, 175, 176
kidney disease (CKD) 120, 123, 124, 126,
130, 132, 168, 171, 173, 174, 177, 178,
188, 189
CNS-dependent pathways 39
Combination therapy 133
Concomitant kidney disease 130
Conditions 11, 23, 30, 35, 40, 173, 176, 182,
187
complicated metabolic 23
reducing hyperglycemic 30
Connective tissue growth factor (CTGF) 175,
176
Conventional insulin delivery systems 37
Coptischinensis 33
Coronary 7, 118, 124, 125, 149, 150, 152
artery disease 7
heart disease (CHD) 118, 124, 125, 149,
150, 152
Cytokines 175, 176, 190
fibrogenic 175
pro-inflammatory 176, 190

D

Deaths 130, 150
cardiovascular 130
vascular 150
Diabetes 2, 3, 7, 9, 11, 22, 24, 31, 34, 36, 37,
38, 39, 40, 59, 68, 73, 75, 79, 80, 85, 86,
87, 88, 90, 94, 96, 139, 142
adherence questionnaire (DAQ) 59, 75, 80,
85, 86, 87, 88, 90, 94, 96
-associated complications 7
care 24, 31, 37, 39, 68, 90
complications 2, 9
drugs 24
family behavior checklist (DFBC) 79
gestational 11
pathogenesis 3, 7, 34
self-management 37, 73
treatment 22, 24, 36, 37, 38, 40, 139, 142
Diabetic 4, 25, 168, 169, 170, 171, 172, 174,
175, 189
atherosclerosis 4
disease 25
kidney disease (DKD) 168, 169, 170, 171,
172, 174, 175, 189
Diarrhea 33, 81, 92, 99, 145, 181, 183, 186,
191
Diet 51, 60, 61, 66, 68, 70, 71, 75, 76, 77, 94,
95, 177, 178, 182
high-fat 51, 177
nutritious 68
Disease 3, 6, 134
pathogenesis 3
process 134
progression 6
Disorders 1, 39, 40, 49, 117, 193
lipodystrophic 193
metabolic 1, 39, 49
sleep 193
Distress, psychosocial 72
Dizziness 92
Drug binding affinity 7
Dynamic light scattering (DLS) 6

Dysfunction 11, 121, 122, 135, 136, 169, 174, 177, 186
associated glomerular barrier 177
cognitive 186
endothelial 169
hemodynamic 174
renal 121, 122, 135, 136
thyroid 11
Dyslipidemia 33, 140, 148, 157, 169
atherogenic 169

E

Eating disorders 69
Effects, kidney-protective 177
Electron microscopy 174
Electrophoresis 6
Emotional feedback (EF) 59, 80, 85, 86, 87, 88, 89, 90, 91, 92, 93, 96, 102, 105
Endothelial nitric oxide synthase 193
End-stage kidney disease (ESKD) 130, 169, 170, 171, 189
Energy expenditure 177, 178
Energy intake 178
nutritional 178
Energy metabolism 129, 193
myocardial 129
Enzymes 12, 26, 27, 33, 128
intestinal 128
ketamine oxidase 12
lipid metabolism 33
malic 26
metabolic 27
Epithelial-to-mesenchymal transition 175
European 11, 24, 49, 52, 185, 186
association for the study of diabetes (EASD) 11, 24
food safety authority (EFSA) 49, 52
medicines agency (EMA) 185, 186

F

Factors 52, 65, 66, 67, 69, 70, 75, 76, 77, 78, 79, 80, 102, 103, 172, 175, 141
adipocyte-derived 52
epigenetic 172
inflammatory 175
risk-enhancing 141
Fatty acyl-CoA synthase 25
Fibrosis 175, 176, 177
Fluorescence spectroscopy 6
Food 49, 50
consumption 49
dietary 50
Free fatty acids (FFAs) 26, 30, 52, 176, 177
Function 27, 32, 51
abnormal hepatocellular 51
antioxidant 32
renal 27

G

Gas chromatography-mass spectrometry (GCMS) 6
Gastric inhibitory polypeptide (GIP) 30, 180, 190
Gastrointestinal 128, 180, 187, 192
disorders 192
endoscopic devices 187
system 128, 180
Gastrojejunostomy 187
Genetics 172
of kidneys in diabetes 172
of nephropathy 172
Genome-wide association studies (GWAS) 172
Glomerular 7, 174, 175, 177, 189
basement membrane (GBM) 174, 177
capillaries, renal 7
feedback 177
hyperfiltration 174, 175, 189
Glucoregulatory 38, 51
dysfunctions 38
response 51

Glucose 2, 3, 4, 6, 7, 10, 11, 24, 26, 32, 33, 34, 50, 51, 128, 131, 133, 175, 176, 177
absorption of 33, 34, 128
fasting serum 32
homeostasis 50, 51
metabolism 7, 51, 133
transporters 26, 176
Glucosuria 1
Glucosylation 1
Glutamic acid decarboxylase (GAD) 9
Glycated proteins 3, 6, 8, 9, 10
Glycogenolysis 30, 51
hepatic 30
Glycolysis 177
Glycopeptides 31
Glycosuria 28, 184
Gut 50, 51
microbes 50
microbiota 51

H

Healthy children and adolescents 77
Hemoglobin-related disease 11
Hemolytic anemia 10
Hepatic dysfunction 51
Hepatotoxicity 145
High 6, 12, 128
performance liquid chromatography (HPLC) 6, 12
risk for cardiovascular disease 128
HMG-CoA reductase 148
Human serum albumin (HSA) 1, 2, 3, 4, 5, 6
Hyperfiltration 169, 188
Hyperglycaemia 3
Hyperglycemia 1, 3, 22, 23, 27, 34, 146, 174, 175, 176
Hyperinsulinemia 28, 169, 176, 177
Hyperperfusion 175
Hypoglycemia 26, 27, 28, 30, 34, 51, 68, 69, 123, 143, 144, 170
diabetic 26
hyperinsulinemic 28
symptomatic 34, 123, 144

Hypoglycemic 23, 50, 51
risk 23
pituitary-adrenal (HPA) 50, 51

I

Immune 4, 8, 9, 13, 36, 154
response 4, 8, 9, 13
system 8, 36, 154
Immunoassays 6, 12
electrochemical 12
enzyme-linked boronate 12
Inflammation 9, 177
chronic 9
hepatic 177
reaction 9
Inflammatory diseases 64
Infrared spectroscopy 6
Infusion, intravenous glucose 180
Inhibition assay 9
Inhibitors 22, 24, 29, 117, 120, 124, 131, 133, 145, 151, 170, 179, 186, 193
alpha-glucosidase 22, 24, 117, 124, 145, 179
gastric lipase 193
monoamine oxidase 186
renin-angiotensin system 170
Insomnia 50, 186
Insulin 1, 2, 3, 24, 26, 28, 29, 34, 35, 36, 39, 49, 51, 53, 61, 65, 66, 70, 71, 72, 75, 95, 133, 142, 144, 145, 180, 192
absorption 29
granule exocytosis 26
injections 24, 39, 61, 70, 144
pathways 53
response 133, 180
therapy 28, 66, 145
tolerance 26
treatment 65, 66, 70, 71, 72
Insulin resistance 24, 35, 50, 51, 52, 169, 173, 185, 188
production 51
Insulin secretion 1, 27, 28, 32, 133, 180, 181
pancreatic 181
Insulin sensitivity 7, 31, 50, 177, 178

adipocyte 7
 Ion-exchange chromatography 12
 Iron deficiency 10
 Ischemic 141, 155
 disease 141
 heart disease 155
 Islet 9, 24
 cytoplasm 9
 neogenesis 24

K

Ketoacidosis 28, 68
 diabetic 28
 Kidney 23, 168, 171, 173, 174, 175, 176, 177,
 183, 188, 189, 190
 failure 168
 fibrosis 177
 function 23, 171, 173, 188
 impairment 176, 183
 inflammation 176
 injury 175, 176
 outcomes 190
 parenchyma 174
 proximal tubule cells (KPTCs) 177
 -related outcomes 173
 transcriptomic response 189
 transplantation 189
 Kidney disease 28, 168, 169, 170, 171, 173,
 177, 178, 179, 180, 181, 187, 189
 diabetes-related 168
 diabetic 168, 169, 171
 global outcomes (KDIGO) 170
 non-diabetic 170

L

Lipid 7, 26
 metabolism 26
 peroxidation 7
 Lipid accumulation 173, 177
 ectopic 173, 177
 hepatic 177

Lipohypertrophy 29
 Lipolysis 33, 177
 Liquid chromatography 6, 12
 high-performance 6, 12
 -mass spectrometry 6
 Liver 11, 26, 50, 177, 181
 cirrhosis 11
 enzymes 181
 failure 26
 function 50
 injury 177
 Low-density lipoproteins 2, 3, 4

M

Macrovascular disease 124
 Management, glycemic 37
 MAP-kinase pathways 7
 Mass spectrometry 6
 liquid chromatography-tandem 6
 Mechanisms 25, 29, 30, 33, 148, 152, 173,
 174, 177, 184, 185, 188, 189, 190
 glucose-dependent 30
 metabolic compensatory 184
 Mediators, inflammatory 173
 Medications 24, 25, 27, 28, 39, 67, 70, 117,
 118, 119, 122, 137, 139, 157, 179, 180,
 184, 185, 186
 anti-diabetes 119, 139, 180
 cardioprotective 118
 cardiovascular 137
 hyperlipidemia 117
 immunosuppressive 39
 lipid-lowering 118, 157
 Medicinal plants 31
 antidiabetic 31
 Medicine 22, 24, 26
 anti-diabetic 26
 glucose-reducing 22
 hypoglycemic 24
 Medullary thyroid carcinoma 181
 Mental 64, 73, 93, 100, 101, 104
 health factors 73, 93, 100, 101
 hygiene 104

transformation 64
Mesenchymal stem cell (MSCs) 35
Metabolic 169, 176, 186, 187
 acidosis 186
 complications 187
 syndrome 169, 176
Metabolism 11, 27, 128, 134
 abnormal haemoglobin 11
 hepatic drug 27
 myocardial 134
Metformin intolerance 27
Methamphetamine 179
Methicillin *Staphylococcus aureus* 33
Methods 12
 electrochemical 12
 enzymatic 12
Microangiopathy 7
Microvascular 68, 169, 170
 complications 68, 170
 damage 169
Mortality 117, 118, 124, 127, 128, 130, 131,
 136, 137, 139, 143, 146, 148, 187, 188
 cardiovascular 118, 124, 127, 130
Myocardial infarction, acute 118

N

Nausea 181, 183, 186, 191
Nephritic syndrome 170
Nephrolithiasis 173, 186
Nephropathy 2, 4, 11, 49, 124, 169, 172
 diabetic 4, 124, 169
Nephrotic syndrome 11
Neurological disease 50
NMR spectroscopy 6
Non-alcoholic fatty liver disease (NAFLD)
 177

O

Oral glucose tolerance test (OGTT) 11
Oxidative stress 5, 173, 175, 176, 177

P

Pancreas 2, 29, 49, 50, 52, 142, 181
 canine 142
Pancreatic lipases 185
Pancreatitis 139, 181, 182, 183
 necrotizing 181
Pathways 7, 148, 174
 biosynthesis 148
 cellular signaling 7
 epigenetic 174
 metabolic 174
Peptide therapy 24
Peroxisome proliferator-activated receptors
 (PPAR) 25, 26, 145
Piper nigrum 32
Plasma 4, 27, 118
 glucose 118
 proteins 4, 27
Problem(s) 23, 39, 40, 79, 81, 82, 193
 coronary 39
 heart 40
 microvascular 23
 neuromuscular 82
 public health 39, 193
 recognition and illness self-management
 (PRISM) 79
 social behaviour 81
Process 5, 37, 65, 66, 175, 177
 flexible self-management 66
 inflammatory 175
Production 3, 4, 7, 24, 36, 51, 142, 173, 175,
 176, 193
 hepatic glucose 51
 nitric oxide 193
 oxidant 176
Pro-inflammatory signaling 177
Protein(s) 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 49
 autologous 4
 glycation 1, 6
 lysine-rich 5
 metabolism 1, 49
 non-enzymatic glycation of 1, 4
 transmembrane 7

Protein kinase 33, 175
 monophosphate-activated 33
 C (PKC) 175
Proteinuria 188, 190

R

Reactive 4, 7, 52, 175
 nitrogen species (RNS) 52
 oxygen species (ROS) 4, 7, 52, 175
Regulation 5, 32
 hepatic glycolysis 32
 oncotic pressure 5
Renal 11, 124, 129, 130
 affection 130
 disease 124
 impairment 11
 -protection 129
Renin-angiotensin-aldosterone system
 (RAAS) 173, 175
Researching cardiovascular events 125
Residues 2, 4, 9
 glycated-lysine 9
 histidine 2
Retinopathy 2, 4, 7, 11, 39, 49, 137, 170, 184
 diabetic 4, 7, 137, 170
Revascularization, coronary 153
Risk factors 51, 143
 cardiometabolic 51
 cardiovascular 143

S

Self-rated health (SRH) 62, 64, 81, 84, 92, 99,
 100, 101
Strengths and difficulties questionnaire (SDQ)
 83, 88, 90, 91, 92, 93
Stroke 118, 119, 120, 121, 122, 123, 124, 126,
 127, 129, 130, 134, 135, 136, 137, 138,
 146, 149, 150, 156
Sweeteners 48, 49, 50, 51, 53
 artificial 48, 50
 caloric 51

natural 49, 50

T

Therapies 34, 37
 immune-modulatory 34
 stem cell transplant 37
Thiazolidinediones 22, 24, 25, 27, 117, 124,
 145, 179, 184
Thrombolysis 124
Transplantation 35, 36, 39, 120, 132, 189
 renal 120, 132
Transporters, electrolyte 129
Tumor necrosis factor 175

U

US preventive services task force (USPSTF)
 179

V

Vascular 24, 122, 150, 151
 disease 24, 150, 151
 pathology 122
Vascular events 127, 139, 149, 150, 155
 adverse 139
 severe 155
Vasoconstriction 175
Vasoconstrictor, reducing 177
Vertical sleeve gastrectomy (VSG) 187, 188
Visceral fat secretory biology 24
Visual analogue scale 82
Vitamins 185, 187
 deficiencies 187
 fat-soluble 185
Vomiting 181, 183, 186, 191

W

World health organization (WHO) 31

Z

Zucker diabetic fatty (ZDF) 189



SHAZIA ANJUM

Dr. Shazia Anjum is the Professor of the Chemistry Department and the Director of Cholistan Institute of Desert Studies, the Islamia University of Bahawalpur, Pakistan. She is experienced medicinal and natural product chemist. She has authored and co-authored more than 120 research papers (Impact Factor: 224.8) and a US patent. She has edited 10 books and has published 03 chapters in international books. She has accomplished the synthesis of several naturally occurring aminoglycosides that can be used as antibiotics. Dozen of students have completed their MS degrees under her supervision and couple of others are pursuing for their MS/PhD degrees.

As recognition of her contributions to science, she has been awarded with 03 International awards like Fellowship from Islamic World Academy of Sciences, Postdoctoral fellowship from Ministry of Culture and Education, Spain and a Young Chemist Award from Third World Academy of Sciences, Italy. She also has several national awards on her credit.